In the News

1893 News Items found
An MSK researcher points at a medical image
New MSK research investigates how a natural antifungal compound produced by helpful gut bacteria might help protect vulnerable patients; finds that a protein “fingerprint” in blood could predict dangerous clots in cancer patients; uncovers Americans’ changing relationship with dietary supplements; and reveals how NK cells respond to infections so quickly.
MSK urologic surgeon Dr. Massimiliano Spaliviero
Read about MSK's personalized approach to diagnosing and treating prostate cancer. This includes expertise in determining whether active surveillance is the best option for low-risk disease and providing the newest treatments for people at higher risk.
Lorenz Studer, Danwei Huangfu, Ting Zhou, Thomas Vierbuchen
MSK scientists are part of an international consortium working to determine the biological functions of the roughly 20,000 protein-coding genes in the human genome.
detail of a scientist holding up a slide
MSK Research Highlights, June 11, 2026
New MSK research decodes how mesothelioma evades immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source AI-driven drug discovery initiative.
Dr. Eileen O'Reilly seen smiling in an exam room.
Learn how a successful clinical trial for pancreatic cancer in which MSK experts play a leading role is opening a new world of treatment options.
Christine Mayr
New MSK research shows the largely overlooked "tail" region of mRNAs helps ensure key regulatory proteins get folded correctly — a fundamentally new understanding of their role.
Nurse Lauren Kidd smiles while looking at a laptop computer
After completing treatment for cancer, the fear that it will come back is normal — and something that can be managed.
Man in the process of blowing glass at end of a long tube.
Article
Learn about a new treatment approach for tongue cancer that allowed a glassblower to continue practicing his art and to find joy in it.
MSK patient Joanne Ferrari-Mautino seen outdoors with her son and boyfriend.
Learn how MSK is helping people with lung cancer driven by ROS1 fusions, thanks to continual improvements in specific targeted therapies.
MSK Chief Scientific Officer Dr. Ross Levine smiles at a trainee in the lab
Learn more about MSK's new Chief Scientific Officer, Dr. Ross Levine, who has dedicated more than 25 years to studying blood and bone marrow cancers: “I believe there has never been a more exciting time for cancer science.”